Skip to Main Content

Paper Details

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.
Br J Haematol
6
2015
BL, Burkitt leukaemia, EOC, EOI, Malins de Burkitt 96 C1, Patient, Patient-specific primers, advanced Burkitt leukaemia, central nervous system disease, children, rituximab
Author NameAffiliation
Sherrie L PerkinsUniversity of Utah
Sherrie L PerkinsUniversity of Utah
  • 1 - 2

Datasets

Release 1.2